


How to bring your crazy idea to first-in-man (FIM) study?

M. Vaturi

Department of Cardiology Rabin Medical Center The Need

Severe TR is bad news



Journal of the American College of Cardiology © 2004 by the American College of Cardiology Foundation Published by Elsevier Inc. Vol. 43, No. 3, 2004 ISSN 0735-1097/04/\$30.00 doi:10.1016/j.jacc.2003.09.036


Impact of Tricuspid Regurgitation on Long-Term Survival

Jayant Nath, MD,* Elyse Foster, MD, FACC,† Paul A. Heidenreich, MD* Palo Alto and San Francisco, California

Severe TR is associated with a poor prognosis, independent of age, biventricular systolic function, RV size, and inferior vena cava dilation.

The prognostic impact appears even with moderate TR

1 of 3 patients with severe TR is dead by the **1**st **year**, **1 of 2** will die within **5 years** !



In 5 years ~35% of the severe TR patients are dead

Topilsky et al. JACC: Cardiovascular Imaging 2014

The Clinical Experience


- High-risk profile combined with old age, frequent previous cardiac interventions, many comorbidities, and the consequences of low cardiac output state (CKD, liver congestion, gut congestion).
- Surgical risk for TR intervention exceeds those of AVR and MVR.
- Prolonged recovery after TV surgery.
- Persistent dependence on high-dose diuretics despite TR elimination.
- The medical therapy is useless to **cure** severe TR.
- The right ventricle




...and there's the V.A.T

Substantial mileage in the O.R and the valvular clinic

When the Current Solution is not Ideal





Topilsky Y. et al. Circ Cardiovasc Imaging 2012;5:314-23



The most used TR repair techniques resulted in approximately 15% severe TR (+3\+4 TR) within five years after the surgery

Navia JL. Et al. J Thorac Cardiovasc Surg 2010;139:1473-82)





Zack, C.J. et al. J Am Coll Cardiol. 2017;70(24):2953-60.

Outcomes of Isolated Tricuspid Valve Surgery Have Improved in the Modern Era



Mohanad Hamandi, MD, Robert L. Smith, MD, William H. Ryan, MD, Paul A. Grayburn, MD, Anupama Vasudevan, PhD, Timothy J. George, MD, J. Michael DiMaio, MD, Kelley A. Hutcheson, MD, William Brinkman, MD, Molly Szerlip, MD, David O. Moore, MD, and Michael J. Mack, MD

Departments of Cardiovascular Research, Cardiothoracic Surgery, and Cardiology, Baylor Scott & White-The Heart Hospital, Plano, Texas

Outcomes	Overall (N = 95)	Repair (n = 68)	$\begin{array}{l} \text{Replacement} \\ (n=27) \end{array}$	<i>p</i> Value
Postoperative stroke	2 (2.1)	1 (1.5)	1 (3.7)	0.49
New requirement for dialysis	5 (5.3)	3 (4.4)	2 (7.4)	0.62
Cardiac tamponade	1 (1.1)	1 (1.5)	0 (0)	1.0
New-onset atrial fibrillation	11 (11.6)	9 (13.2)	2 (7.4)	0.72
New pacemaker	16 (16.8)	8 (11.8)	8 (29.6)	0.06
In-hospital mortality	2 (2.1)	2 (2.9)	0 (0)	1.0
Readmission	9 (9.5)	4 (5.9)	5 (18.5)	0.11
30-day mortality	3 (3.2)	3 (4.4)	0 (0)	0.56
Initial ICU stay (hours)	$\begin{array}{r} 133.8\ \pm\\200.3\end{array}$	129.8 ± 195.8	143.8 ± 214.9	0.76
Length of stay (days)	$\begin{array}{c} 11.6 \ \pm \\ 10.6 \end{array}$	11.1 ± 9.6	12.8 ± 12.8	0.50



"We believe that our low operative mortality rate is the result of improved patient selection resulting from increasing experience, careful preoperative assessment, and pre-and postprocedural management leading to earlier patient referral." The Itch

"There's a fine line between fishing and just standing on the shore like an idiot"


Steven Wright




Transforming an idea to a sophisticated model



Let's pour some innovation into this valve






- Anchoring onto a "virtual annulus"
- Avoiding pressure on the adjacent conduction system
- A sizeable effective orifice area
- Something to alleviate the abrupt rise in RV's afterload immediately upon elimination of severe TR: a parachutelike valve with a closing volume
- A transcatheter valve



The Via Dolorosa to the Pocket





Meanwhile


The hard and tedious work in the lab.




A consorted effort of engineers, technicians, secretaries, CEO...and me.

In Vitro => In Vivo (animals) => FIM

Better have these for ...



...this moment



...and this moment



TIS1.2 MI 1.1


M1 M4 +61.6

> -61.6 cm/s


Think Positive, Be Prepared for Dissapointments



HIGH EXPECTATIONS



ACHIEVEMENTS (so far...)



VS.

Who Dares Wins





Thank You for Your Attention